&l;p&g;Come October of 2018 and Canada will become one of the few developed countries to legalize recreational marijuana for adult-use. This revolutionary move has not only sent a wave of joy in the people of the country, but has also turned into a massive business opportunity for cannabis manufacturers, who had been restricting their output to only medical use until now. Consequently, pot stocks such as Canopy Growth has seen a surge in its stock price in the last few months, as investors are trying to leverage on the potential upside that the stock can offer. The company also has a partnership whereby &l;a href=&q;https://www.forbes.com/companies/constellation-brands/&q;&g;Constellation Brands&l;/a&g; (NYSE: STZ) has a 9.9% stake in the company.
However, the medical marijuana producer witnessed an initial sharp drop in its price after it released its fourth quarter and fiscal 2018 results. The stock plunged more than 10% to CAD 36.93 per share, as the company failed to meet the consensus expectations on both the revenue as well as earnings front. We figure that this is a market over-reaction to the earnings miss and believe that the stock has a huge upside potential with the opening up of the recreational marijuana market in third quarter of fiscal 2019. We have a &l;a href=&q;http://dashboards.trefis.com/no-login-required/8o4SkdRX&q; target=&q;_blank&q;&g;price estimate of CAD 53 per share for Canopy Growth&l;/a&g;.
Top Medical Stocks To Watch For 2019: Flushing Financial Corporation(FFIC)
- [By Ethan Ryder]
Flushing Financial Co. (NASDAQ:FFIC) declared a quarterly dividend on Wednesday, May 30th, RTT News reports. Stockholders of record on Monday, June 11th will be paid a dividend of 0.20 per share by the bank on Friday, June 29th. This represents a $0.80 annualized dividend and a dividend yield of 2.96%.
Top Medical Stocks To Watch For 2019: Anavex Life Sciences Corp.(AVXL)
- [By Joseph Griffin]
Medpace (NASDAQ: MEDP) and Anavex Life Sciences (NASDAQ:AVXL) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, dividends and analyst recommendations.
- [By Joseph Griffin]
News stories about Anavex Life Sciences (NASDAQ:AVXL) have trended somewhat positive recently, Accern reports. The research group identifies negative and positive media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Anavex Life Sciences earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 46.1730416635586 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
- [By Shane Hupp]
Here are some of the media stories that may have effected Accern’s analysis:
Get Anavex Life Sciences alerts:
Comparing Anavex Life Sciences (AVXL) & Viralytics (VRACY) (americanbankingnews.com) Hot Move to Watch Anavex Life Sciences Corp. (AVXL) (nasdaqplace.com) Anavex Life Sciences (AVXL) and Intrexon (XON) Head to Head Review (americanbankingnews.com) -$0.10 EPS Expected for Anavex Life Sciences (AVXL) This Quarter (americanbankingnews.com)
A number of equities analysts recently issued reports on the stock. Maxim Group reaffirmed a “buy” rating and set a $7.00 target price (up previously from $5.00) on shares of Anavex Life Sciences in a research report on Thursday, May 31st. Zacks Investment Research lowered shares of Anavex Life Sciences from a “buy” rating to a “hold” rating in a research report on Friday, March 23rd. Noble Financial set a $7.00 target price on shares of Anavex Life Sciences and gave the stock a “buy” rating in a research report on Wednesday, May 16th. HC Wainwright assumed coverage on shares of Anavex Life Sciences in a research report on Wednesday, May 30th. They set a “buy” rating and a $10.00 target price on the stock. Finally, Roth Capital initiated coverage on shares of Anavex Life Sciences in a research report on Thursday, March 8th. They set a “buy” rating and a $6.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Anavex Life Sciences presently has an average rating of “Buy” and an average target price of $6.55.
Top Medical Stocks To Watch For 2019: Voya International High Dividend Equity Income Fund(IID)
- [By Logan Wallace]
ING International High (NYSE:IID) announced a monthly dividend on Wednesday, May 16th, Wall Street Journal reports. Shareholders of record on Monday, June 4th will be given a dividend of 0.052 per share on Friday, June 15th. This represents a $0.62 dividend on an annualized basis and a yield of 9.12%. The ex-dividend date of this dividend is Friday, June 1st.
Top Medical Stocks To Watch For 2019: Safety Insurance Group Inc.(SAFT)
- [By Ethan Ryder]
BidaskClub cut shares of Safety Insurance Group (NASDAQ:SAFT) from a strong-buy rating to a buy rating in a research report released on Friday.
Several other research analysts also recently weighed in on the stock. Compass Point raised shares of Safety Insurance Group from a sell rating to a neutral rating and set a $70.00 target price for the company in a research note on Thursday, March 8th. ValuEngine raised shares of Safety Insurance Group from a hold rating to a buy rating in a research note on Saturday, June 2nd.
- [By Jordan Wathen]
Safety Insurance Group (NASDAQ:SAFT) reported that winter weather activity and an accounting change were drags on its first-quarter results, though a lower tax rate was a net positive to the Massachusetts-based insurance company.
- [By Max Byerly]
Safety Insurance Group, Inc. (NASDAQ:SAFT) Director Frederic H. Lindeberg sold 2,000 shares of the business’s stock in a transaction dated Wednesday, June 6th. The shares were sold at an average price of $88.36, for a total value of $176,720.00. Following the completion of the sale, the director now directly owns 16,000 shares of the company’s stock, valued at $1,413,760. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Top Medical Stocks To Watch For 2019: Immunomedics, Inc.(IMMU)
- [By Todd Campbell]
After unveiling positive results for its lead drug, sacituzumab govitecan, in breast cancer at the influential American Society of Clinical Oncology (ASCO) conference, shares in Immunomedics (NASDAQ:IMMU) rallied by as much as 14.7% today before settling in for a gain of 9.3% at 3 p.m. EDT.
- [By Ethan Ryder]
Teachers Advisors LLC increased its position in shares of Immunomedics (NASDAQ:IMMU) by 14.9% in the 4th quarter, HoldingsChannel reports. The firm owned 211,706 shares of the biopharmaceutical company’s stock after purchasing an additional 27,385 shares during the period. Teachers Advisors LLC’s holdings in Immunomedics were worth $3,421,000 at the end of the most recent reporting period.
- [By Dan Caplinger]
Monday began the week on a solid note for the stock market, with the Dow Jones Industrial Average posting another triple-digit gain as the Nasdaq Compositeclosed at a record high. Despite ongoing nervousness regarding trade, most investors remain convinced that the strong U.S. economy will be able to lead the way forward, pointing to Friday’s employment report as the latest evidence of sustainable momentum. Good news regarding a host of companies both in the U.S. and abroad also helped buoy the market’s mood. Fossil Group (NASDAQ:FOSL), Companhia Siderurgica Nacional (NYSE:SID), and Immunomedics (NASDAQ:IMMU) were among the best performers on the day. Here’s why they did so well.
- [By Logan Wallace]
Rock Springs Capital Management LP bought a new position in Immunomedics, Inc. (NASDAQ:IMMU) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 450,000 shares of the biopharmaceutical company’s stock, valued at approximately $6,575,000. Rock Springs Capital Management LP owned 0.27% of Immunomedics at the end of the most recent reporting period.